SEC Filing Summary: Blade Air Mobility, Inc. (BLDE)
Business Context and Reporting Period
This summary covers the Unaudited Interim Condensed Consolidated Financial Statements for the quarterly period ended June 30, 2024. Blade Air Mobility, Inc. operates an asset-light air transportation model with two primary segments: Passenger (Short Distance helicopter/seaplane flights and Jet charters) and Medical (MediMobility organ transport). The company is transitioning toward Electric Vertical Aircraft (EVA) technology.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $119,459 |
| Net Loss | $(15,560) |
| Loss Per Share (Basic & Diluted) | $(0.20) |
| Adjusted EBITDA | $(2,588) |
| Flight Profit | $26,493 |
| Flight Margin | 22.2% |
| Cash and Cash Equivalents | $26,308 |
| Short-term Investments | $115,643 |
| Total Liquidity | $142,000 |
| Debt | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 12% year-over-year (YoY) to $119.5 million, driven primarily by a 22% increase in the Medical segment ($74.4M) due to new hospital clients and higher revenue per trip. The Passenger segment remained flat YoY ($45.1M) as growth in Short Distance flights was offset by the discontinuation of seasonal Jet services.
- Profitability Improvement: Net loss narrowed significantly to $15.6M from $22.4M in the prior year. Adjusted EBITDA improved by $9.6M to a loss of $2.6M, moving closer to breakeven.
- Cost Efficiency: Cost of revenue as a percentage of revenue decreased from 83% to 78%, attributed to the utilization of owned aircraft in the Medical segment starting April 2024 and improved pricing in the Passenger segment.
- Impairment Charge: A non-cash impairment charge of $5.8M was recorded related to exclusive air transportation rights for Blade Canada, impacting General and Administrative expenses.
- Asset Acquisition: The company acquired seven aircraft for approximately $17.6M to support the Medical business, funded by cash and prepaid deposits.
Outlook, Risks, and Management Commentary
- Liquidity: Management states that with $142M in liquid funds, the company has sufficient capital to meet operational needs for at least the next 12 months without additional financing.
- Share Repurchase: A $20M stock repurchase program was authorized in March 2024. As of June 30, 2024, the company repurchased 80,102 shares for $0.2M, leaving approximately $19.8M remaining capacity.
- Internal Controls: Management disclosed that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in IT General Controls (user access and change management) and revenue process controls. Remediation efforts are ongoing.
- Legal Proceedings: The company is defending against a consolidated class action lawsuit (Drulias et al. v. Affeldt) regarding the 2021 merger, which management believes is without merit.
- Strategic Focus: Continued focus on transitioning to EVA technology and expanding the Medical segment, which demonstrated strong profitability (13.4% Adjusted EBITDA margin).
Investor Verification Checklist
- Remediation Timeline: Verify the progress of remediation plans for the material weaknesses in internal controls over financial reporting.
- Medical Segment Sustainability: Assess the durability of the 22% revenue growth in the Medical segment and the impact of owned aircraft on long-term margins.
- Passenger Segment Seasonality: Monitor the impact of the discontinued seasonal Jet service on future Passenger revenue stability.
- Legal Exposure: Track developments in the Drulias litigation and potential financial impact.
- Capital Allocation: Review the execution of the $20M share repurchase program and future capital expenditure plans for EVA integration.